Suchergebnisse - "Balar, Arjun V"

PubPharm (14)

1

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma : Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial

enthalten in: The oncologist | 2023

von Larkin, J. | Oya, M. | Martignoni, M. | +16

2

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma : Results from PIVOT-02

enthalten in: European urology | 2022

von Siefker-Radtke, A. | Cho, D. | Diab, A. | +15

CommentIn: Eur Urol. 2022 Oct;82(4):374-376. - PMID 35752503

3

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer : A Multicenter, Single-Arm, Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Funt, S. | Lattanzi, M. | Whiting, K. | +36

CommentIn: J Clin Oncol. 2022 Aug 10;40(23):2656. - PMID 35609220

4

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma : results from the PIVOT-02 study

enthalten in: Journal for immunotherapy of cancer | 2022

von Tannir, N. | Cho, D. | Diab, A. | +15

5

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057) : an open-label, single-arm, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Balar, A. | Kamat, A. | Kulkarni, G. | +15

CommentIn: Nat Rev Urol. 2021 Oct;18(10):577-578. - PMID 34230659

6

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Yu, E. | Petrylak, D. | O'Donnell, P. | +17

CommentIn: Lancet Oncol. 2021 Jun;22(6):748-749. - PMID 33991513

7

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

8

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

enthalten in: Journal of translational medicine | 2019

von Labadie, B. | Liu, P. | Bao, R. | +9

9

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Rosenberg, J. | O'Donnell, P. | Balar, A. | +10

CommentIn: J Clin Oncol. 2019 Oct 10;37(29):2587-2591. - PMID 31260641

10

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer

enthalten in: The oncologist | 2019

von Osterman, C. | Babu, D. | Geynisman, D. | +13

CommentIn: Oncologist. 2019 May;24(5):580-583. - PMID 30926675